Sucampo Pharmaceuticals Company Profile (NASDAQ:SCMP)

Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) posted its earnings results on Wednesday, August, 2nd. The company reported $0.28 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.22 by $0.06. The business had revenue of $59.90 million for the quarter, compared to analysts' expectations of $56.44 million. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The business's revenue for the quarter was up 15.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.24 EPS. View Sucampo Pharmaceuticals' Earnings History.

Sucampo Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals issued an update on its FY17 earnings guidance on Tuesday, September, 26th. The company provided earnings per share guidance of $1.00-1.10 for the period, compared to the Thomson Reuters consensus estimate of $1.03. The company issued revenue guidance of $220-230, compared to the consensus revenue estimate of $234.66 million.

6 brokers have issued 12 month price objectives for Sucampo Pharmaceuticals' shares. Their forecasts range from $11.00 to $30.00. On average, they expect Sucampo Pharmaceuticals' share price to reach $17.67 in the next twelve months. View Analyst Ratings for Sucampo Pharmaceuticals.

Here are some recent quotes from research analysts about Sucampo Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Sucampo is focused on expanding Amitiza’s label and penetrating new markets. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Also, through the agreement with Cancer Prevention Pharmaceuticals, Sucampo acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, dependence of Sucampo on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. A decline in Amitiza's sales will adversely impact the top line. Moreover, it had its share of pipeline setbacks. Shares of the company have underperformed the industry. Estimates have remained stable ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in the recent quarters." (10/17/2017)
• 2. Maxim Group analysts commented, "Sucampo has acquired privately owned Vtesse Inc. and its lead orphan drug candidate for Niemann-Pick Type C1, VTS-270, for $170M in cash & the rest in stock: total of $200M. There is also a contingent earn-out (payments in the mid-single digit to double-digit royalties on global net sales) of the product at increasing net sales levels." (4/3/2017)
• 3. Jefferies Group LLC analysts commented, "Post the Q4 results and guidance we have revisited our assumptions and are making two changes to our model reflecting ' 1) likely Amitiza mandated price erosion in Japan and 2) our switch projections for the alternative formulation of Amitiza. We also fine-tune our FY17 revs and EPS estimates. We continue to view potential business development/M&A as critical to the longer term outlook given the finite life of Amitiza and await mgt's plans." (3/17/2017)
• 4. Mizuho analysts commented, "We reiterate our Buy rating and $16 PT into the 4Q:16 print on March 8. The near-term Amitiza outlook remains favorable in both the U.S. and Japanese markets, which we believe may support additional optionality for the company in front of its 2021 patent cliff." (3/6/2017)

Some companies that are related to Sucampo Pharmaceuticals include Ignyta (RXDX), Retrophin (RTRX), Omeros Corporation (OMER), Amarin Corporation PLC (AMRN), Flexion Therapeutics (FLXN), Intra-Cellular Therapies (ITCI), Akebia Therapeutics (AKBA), Reata Pharmaceuticals (RETA), ZIOPHARM Oncology (ZIOP), Revance Therapeutics (RVNC), Cytokinetics, Incorporated (CYTK), Alder BioPharmaceuticals (ALDR), La Jolla Pharmaceutical Company (LJPC), Keryx Biopharmaceuticals (KERX), CytomX Therapeutics (CTMX), PTC Therapeutics (PTCT), Vanda Pharmaceuticals (VNDA) and Coherus BioSciences (CHRS).

Sucampo Pharmaceuticals' management team includes the folowing people:

• Peter S. Greenleaf, Chairman of the Board, Chief Executive Officer
• Peter P. Pfreundschuh CPA, Chief Financial Officer, Principal Financial Officer
• Max Donley, Executive Vice President of Human Resources
• Thomas J. Knapp, Executive Vice President, Chief Legal Officer and Corporate Secretary
• Matthias Alder, Executive Vice President
• Stanley G. Miele, Senior Vice President - Sales and Marketing; President of Sucampo Pharma Americas, LLC
• Peter A. Kiener Ph.D., Chief Scientific Officer
• Alex Driggs, General Counsel, Corporate Secretary
• Peter Lichtlen M.D., Ph.D., Chief Medical Officer
• John H. Johnson, Lead Independent Director

Sucampo Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Eqis Capital Management Inc. (0.09%). Company insiders that own Sucampo Pharmaceuticals stock include Andrew P Smith, Daniel P Getman, Jason Patrick Meyenburg, Jones W Bryan, Matthias Alder, Peter Greenleaf and Sachiko Kuno. View Institutional Ownership Trends for Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. Company insiders that have bought Sucampo Pharmaceuticals stock in the last two years include Jason Patrick Meyenburg and Jones W Bryan. View Insider Buying and Selling for Sucampo Pharmaceuticals.

Shares of Sucampo Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Sucampo Pharmaceuticals stock can currently be purchased for approximately $10.30.